跳至主要内容
临床试验/ACTRN12611000491965
ACTRN12611000491965已完成3 期

Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial

niversity of Adelaide0 个研究点目标入组 1,679 人开始时间: 2011年5月11日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
1,679

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
16 Years 至 50 Years(—)
性别
Female

入选标准

  • Women are eligible for the trial if they are at risk of preterm birth between 30 and 34 weeks’ gestation where birth is planned or definitely expected within 24 hours, have a singleton or twin pregnancy, no contraindications to the use of antenatal magnesium sulphate (myasthenia gravis, respiratory depression, hypotension, absent patellar reflexes or renal failure) and give informed, written consent.

排除标准

  • Women are not eligible if they have a higher-order multiple pregnancy, have already received antenatal magnesium sulphate or if magnesium sulphate therapy is considered essential for the treatment of pre-eclampsia.

研究者

发起方
niversity of Adelaide

相似试验